
2025 outlook for medtech in China
Policy shifts, procurement pressures, and expanded early access are reshaping China’s medtech sector. Our experts unpack the impact of VoBP expansion, price transparency mandates, early access programs, and evolving reimbursement models on market access and commercial strategy.
2024 was eventful for China’s medtech industry: the Medical Device Management Law was seen as a positive, especially for innovative therapies. Meanwhile, volume-based procurements and price transparency requirements brought ongoing price pressure to the industry. More early access opportunities are now available in pilot zones, while new reimbursement pathways and innovative payment schemes are emerging across key regions.
More recently, the trade conflict between US and China has brought about more uncertainties, especially for those with global footprints and high stakes in both markets. Based on our annual survey and ongoing dialogues with industry leaders, Simon-Kucher has…
